Press release
Lupkynis Market is Expected to Show a Healthy Growth Rate During the Study Period (2019-2032)| Key Companies- Aurinia Pharmaceuticals
Lupkynis Market
Download Sample Report to know more @https://www.delveinsight.com/sample-request/lupkynis-market-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr
Lupkynis Overview
LUPKYNIS (voclosporin) is an orally administered calcineurin-inhibitor (CNI) immunosuppressant that has demonstrated improvement in near and long-term outcomes in Lupus Nephritis (LN) when used in combination with a background immunosuppressive therapy regimen for the treatment of adult patients with active LN. By inhibiting calcineurin, LUPKYNIS reduces cytokine activation and blocks interleukin IL-2 expression and T-cell-mediated immune responses.
LUPKYNIS is a calcineurin-inhibitor immunosuppressant. The mechanism of voclosporin suppression of calcineurin has not been fully established. Activating lymphocytes involves an increase in intracellular calcium concentrations that bind to the calcineurin regulatory site and activate calmodulin-binding catalytic subunit and through dephosphorylation activates the transcription factor, nuclear factor of activated T-cell cytoplasmic (NFATc). The immunosuppressant activity inhibits lymphocyte proliferation, T-cell cytokine production, and expression of T-cell activation surface antigens.
The recommended starting dose of LUPKYNIS is 23.7 mg twice a day. It is recommended to use LUPKYNIS in combination with mycophenolate mofetil (MMF) and corticosteroids.
Click here to learn more about the Lupkynis Market Landscape @https://www.delveinsight.com/report-store/lupkynis-market-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr
Lupkynis Treatment Market
Lupkynis is a medicine used to treat lupus nephritis, a manifestation of a disease called systemic lupus erythematosus. In lupus nephritis, the immune system (the body's natural defences) attacks the kidneys, causing inflammation and kidney damage
Learn more about the treatment market for Lupkynis @ https://www.delveinsight.com/report-store/lupkynis-market-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr
The Report Covers the Lupkynis Epidemiology Segmented by:
Lupkynis prevalent cases
Lupkynis incident Cases
Lupkynis treatment cases
Lupkynis diagnosed cases
Lupkynis Dug Profile and Companies Covered
Aurinia Pharmaceuticals: LUPKYNIS
And many others
Learn more about the Key Companies and Emerging Therapies in the Hemophilia Market @ https://www.delveinsight.com/report-store/lupkynis-market-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr
Table of Contents
Key Insights
Lupkynis Introduction
Executive Summary of Lupkynis
Disease Background and Overview
Lupkynis Epidemiology and patient population
Lupkynis Emerging Therapies
Lupkynis Market Outlook
Lupkynis Market Access and Reimbursement of Therapies
Lupkynis Market Drivers
Lupkynis Market Barriers
Appendix
Lupkynis Report Methodology
DelveInsight Capabilities
Disclaimer
Learn about the detailed offerings of the Lupkynis Market Outlook report @
https://www.delveinsight.com/report-store/Lupkynis -market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr
Related Reports
Lupkynis Epidemiology Forecast
https://www.delveinsight.com/report-store/Lupkynis -epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr
Lupkynis Pipeline Forecast
https://www.delveinsight.com/report-store/Lupkynis -pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr
Trending Reports By DelveInsight:
Functional Constipation Market
https://www.delveinsight.com/report-store/chronic-constipation-market
Lebers Hereditary Optic Neuropathy Lhon Market https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market
Gastric Neuroendocrine Tumors Market
https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market
Immune Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market
Visceral Pain Associated With GI Disorders Market
https://www.delveinsight.com/report-store/visceral-pain-associated-with-gi-disorders-market
Bullous Pemphigoid Market
https://www.delveinsight.com/report-store/bullous-pemphigoid-market
Cyclin-dependent Kinase-like 5 Deficiency Disorder Market https://www.delveinsight.com/infographics/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market
Myocarditis Market
https://www.delveinsight.com/report-store/myocarditis-market
Recurrent Blood Clots Market
https://www.delveinsight.com/report-store/recurrent-blood-clots-thrombophilia-market
Zollinger-ellison Syndrome Market
https://www.delveinsight.com/report-store/zollinger-ellison-syndrome-market
Age-related Hearing Loss Medical Device Market
https://www.delveinsight.com/blog/age-related-hearing-loss-device-market
Heart Sounds Sensors Market
https://www.delveinsight.com/report-store/heart-sounds-sensors-electronic-stethoscope-market
Hypoplastic Left Heart Syndrome Hlhs Market
https://www.delveinsight.com/report-store/hypoplastic-left-heart-syndrome-market
Infectious Arthritis/Septic Arthritis Market
https://www.delveinsight.com/report-store/infectious-arthritisseptic-arthritis-market
Plasmacytoma Market
https://www.delveinsight.com/report-store/plasmacytoma-market
Agoraphobia Market
https://www.delveinsight.com/report-store/agoraphobia-market
Clinically Isolated Syndrome CIS Market
https://www.delveinsight.com/report-store/clinically-isolated-syndrome-cis-market
Fucosidosis Market
https://www.delveinsight.com/report-store/fucosidosis-market
Major Depressive Disorder Market
https://www.delveinsight.com/report-store/major-depressive-disorder-market
Neuronal Ceroid-lipofuscinoses Market
https://www.delveinsight.com/report-store/neuronal-ceroid-lipofuscinoses-cln1-disease-market
Orthotic Devices Market
https://www.delveinsight.com/report-store/orthotic-devices-market
DelveInsight Business Research LLP
Adya Kaul
info@delveinsight.com
https://www.delveinsight.com
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lupkynis Market is Expected to Show a Healthy Growth Rate During the Study Period (2019-2032)| Key Companies- Aurinia Pharmaceuticals here
News-ID: 3156806 • Views: …
More Releases from DelveInsight Business Research LLP
Paroxysmal Nocturnal Hemoglobinuria Treatment Pipeline Shows Strong Momentum as …
DelveInsight's, "Paroxysmal Nocturnal Haemoglobinuria Pipeline Insight 2026" report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Paroxysmal Nocturnal Haemoglobinuria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Sarcopenia Clinical Trial Pipeline Appears Robust With 18+ Key Pharma Companies …
DelveInsight's "Sarcopenia Pipeline Insight 2026" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Sarcopenia pipeline landscape. It covers the Sarcopenia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Sarcopenia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Sarcopenia Research. Learn more about…
Thymidine Kinase 2 Deficiency Market is projected to grow at a CAGR of 50% by 20 …
DelveInsight's "Thymidine Kinase 2 Deficiency Market Insight, Epidemiology and Market Forecast - 2034" report delivers an in-depth analysis of Thymidine Kinase 2 Deficiency epidemiology, market, and clinical development understanding, Addition to this report provides historical and forecasted epidemiology and market data as well as a detailed analysis on the Thymidine Kinase 2 Deficiency therapeutics market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom,…
Lupus Nephritis Clinical Trial Pipeline Appears Robust With 35+ Key Pharma Compa …
DelveInsight's "Lupus Nephritis Pipeline Insight 2026" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in the Lupus Nephritis pipeline landscape. It covers the Lupus Nephritis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Lupus Nephritis Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates…
More Releases for Lupkynis
Lupus Nephritis Market Expected to Gain Momentum Through 2034, According to Delv …
The Lupus Nephritis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Lupus Nephritis pipeline products will significantly revolutionize the Lupus Nephritis market dynamics.
DelveInsight's "Lupus Nephritis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Lupus Nephritis, historical and forecasted epidemiology as well as the Lupus Nephritis market trends in the United…
Lupus nephritis Market Size was USD 1.8 billion in 2024, estimates DelveInsight
In 2024, the Lupus Nephritis market was valued at approximately USD 1.8 billion, with BENLYSTA and LUPKYNIS - the only FDA-approved treatments, accounting for the majority of revenues.
A robust late-stage pipeline, featuring candidates such as Novartis' ianalumab, FABHALTA, and CAR-T-based therapies, along with biologics like GAZYVA and SAPHNELO, is anticipated to broaden the therapeutic landscape and fuel market expansion through 2034.
Lupus nephritis (LN) represents a serious renal manifestation of…
Lupus Nephritis Market Analysis 2034 - Competitive Landscape, Clinical Trials, M …
The Lupus Nephritis (LN) market was valued at approximately USD 1.8 billion in 2024 and is projected to expand steadily from 2025 to 2034, driven by the introduction of emerging therapies across the seven major markets (7MM).
Lupus Nephritis Market Summary
In Japan, the Lupus Nephritis market size was around USD 49 million in 2024, and it is anticipated to grow throughout the forecast period (2025-2034). Lupus Nephritis, a serious complication of…
Lupus Nephritis Market Outlook 2034 - Clinical Trials, Market Size, Medication, …
The Lupus nephritis market was valued at around USD 1.8 billion in 2024 and is expected to grow during 2025-2034 due to these emerging therapies in 7MM.
Lupus Nephritis Market Summary
The Lupus nephritis market size in Japan was USD ~49 million in 2024, which is expected to rise during the forecast period (2025-2034). Lupus nephritis, a severe complication of SLE, affects 40-60% of patients, with 10-30% potentially progressing to end-stage renal…
Investigation announced for Investors in shares of Aurinia Pharmaceuticals Inc. …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Aurinia Pharmaceuticals Inc..
Investors who are current long term investors in Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: AUPH stocks follows a lawsuit filed against Aurinia…
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) Investor Notice: Deadline in Lawsuit …
A deadline is coming up on June 14, 2022 in the lawsuit filed for certain investors of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) over alleged securities laws violations by Aurinia Pharmaceuticals Inc.
Investors who purchased shares of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) have certain options and there are strict and short deadlines running. Deadline: June 14, 2022. NASDAQ: AUPH stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
